scholarly journals Therapeutic Mechanisms of Action for Hyperbaric Oxygen on Femoral Head Necrosis

2018 ◽  
Author(s):  
Gerardo Bosco ◽  
Alex Rizzato ◽  
Giuliano Vezzani ◽  
Vincenzo Zanon ◽  
Enrico Camporesi
Keyword(s):  
Femoral Head ◽  
Hyperbaric Oxygen ◽  
Mechanisms Of Action ◽  
Femoral Head Necrosis ◽  
Therapeutic Mechanisms

Review on hyperbaric oxygen treatment in femoral head necrosis

2017 ◽  
Vol 44 (6) ◽  
pp. 497-508 ◽  
Author(s):  
Enrico Camporesi ◽  
◽  
Giuliano Vezzani ◽  
Vincenzo Zanon ◽  
Daniele Manelli ◽  
...  
Keyword(s):  
Femoral Head ◽  
Hyperbaric Oxygen ◽  
Femoral Head Necrosis ◽  
Hyperbaric Oxygen Treatment ◽  
Oxygen Treatment

Clinical effect of hyperbaric oxygen therapy in the treatment of femoral head necrosis

2016 ◽  
Vol 46 (5) ◽  
pp. 440-446 ◽  
Author(s):  
Wei Li ◽  
Ziliang Ye ◽  
Wei Wang ◽  
Kun Wang ◽  
Lang Li ◽  
...  
Keyword(s):  
Femoral Head ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Clinical Effect ◽  
Femoral Head Necrosis

Hyperbaric Oxygen Therapy in Femoral Head Necrosis

2010 ◽  
Vol 25 (6) ◽  
pp. 118-123 ◽  
Author(s):  
Enrico M. Camporesi ◽  
Giuliano Vezzani ◽  
Gerardo Bosco ◽  
Devanand Mangar ◽  
Thomas L. Bernasek
Keyword(s):  
Femoral Head ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Femoral Head Necrosis

Hyperbaric Oxygen Therapy in Femoral Head Necrosis

2010 ◽  
Vol 25 (3) ◽  
pp. e28
Author(s):  
Giuliano Vezzani ◽  
Thomas Bernasek ◽  
Devanand Mangar ◽  
Enrico Camporesi ◽  
Gerardo Bosco
Keyword(s):  
Femoral Head ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Femoral Head Necrosis

scholarly journals Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients

2017 ◽  
Vol 32 (1) ◽  
pp. 707-711 ◽  
Author(s):  
Giuliano Vezzani ◽  
Silvia Quartesan ◽  
Pasqua Cancellara ◽  
Enrico Camporesi ◽  
Devanand Mangar ◽  
...  
Keyword(s):  
Femoral Head ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Femoral Head Necrosis

Avascular necrosis of the femoral head: Evaluation of hyperbaric oxygen therapy and quality of life

2020 ◽  
pp. 561-569
Author(s):  
Angeliki Chandrinou ◽  
◽  
Anna Korompeli ◽  
Eirini Grammatopoulou ◽  
Konstantina Gaitanou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Femoral Head ◽  
Avascular Necrosis ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Harris Hip Score ◽  
Controlled Study ◽  
Second Phase

Introduction: The treatment of avascular necrosis of the femoral head (AVNFH) is based on invasive (e.g., core decompression) and non-invasive methods (e.g., hyperbaric oxygen therapy – HBO2). The purpose of the present study is to evaluate the effect of HBO2 on the quality of life (QoL) of patients with AVNFH. Methods: This was a prospective observational non-controlled study of patients with AVNFH treated by HBO2. It was conducted, with the use of Steinberg scale, on 73 patients with AVNFH Stage I or II who were treated with HBO2. Patients’ QoL was assessed with EuroQol-5D-5L (EQ), Harris Hip Score (mHHS), MAHORN (MHOT), and VAS, in three different phases: before HBO2; after the completion of the first phase (20 HBO2 sessions, up to two months); and after the completion of the second phase (20 HBO2 sessions, up to two months after the first phase). A reassessment was made on the completion of each phase. Ratings were also made after the completion of each phase, over the first five months of follow-up. Results: All 73 patients (67.1% males, 32.9% females, mean age: 40.34, SD ± 9.99) participated in the study. Steinberg scale, mean EQ (F (1, 57) = 25.18, η2 = .306 and F (1, 43) = 43.402, η2 = .502); mHHS (F (1, 61) = 67.13, η2 = .524) and F (1, 43) = 31.84, η2 = .425); MHOT (F (1, 61) = 11.68, η2 = .161) and F (1, 43) = 98.01, η2 = .695); and VAS (F (1, 53) = 24.11, η2 = .313) and F (1, 39) = 45.61, η2 = .539), improved between the first and second measurements and between the second and third measurement accordingly (p < .01). Conclusions: HBO2 treatment does not induce alteration of quality of life and is well tolerated and accepted by patients.

scholarly journals Reply to “Can femoral head necrosis induced by steroid therapy in patients infected with coronaviruses be reversed?”

Bone Research ◽  
2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Peixun Zhang ◽  
Jiabao Ju ◽  
Na Han ◽  
Baoguo Jiang
Keyword(s):  
Femoral Head ◽  
Steroid Therapy ◽  
Femoral Head Necrosis

Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study

Lupus ◽  
2021 ◽  
pp. 096120332110211
Author(s):  
Yin Long ◽  
Shangzhu Zhang ◽  
Jiuliang Zhao ◽  
Hanxiao You ◽  
Li Zhang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systemic Lupus Erythematosus ◽  
Risk Factor ◽  
Femoral Head ◽  
Lupus Erythematosus ◽  
Femoral Head Necrosis ◽  
Joint Involvement ◽  
Multiple Site ◽  
Systemic Lupus ◽  
Cns Involvement

Objective Osteonecrosis (ON), which can lead to physical disability, is a common complication of systemic lupus erythematosus (SLE). The purpose of this study was to determine the prevalence of ON and identify possible risk factors in Chinese SLE patients. Methods SLE patients who fulfilled the 1997 American College of Rheumatology SLE classification criteria were recruited from the Peking Union Medical College Hospital. The chi-square test (χ 2 test) and multivariate regression analyses were used to evaluate risk factors. The Cox proportional-hazards model was used to construct the survival curves and estimate the simultaneous effects of prognostic factors on survival. Results We consecutively enrolled 1,158 patients, of which 88 patients (7.6%) developed ON. Among ON patients, 57.1% of patients had isolated femoral head necrosis and 42.9% had multiple joint involvement. The mean age of ON patients (24.62 ± 8.89 years) was significantly younger than SLE patients without ON (27.23 ± 10.16 years, p = 0.09). The ON group presented with a much longer disease course (10.68 ± 5.97 years, p < 0.001) and increased incidence of arthritis, kidney, and central nervous system (CNS) involvement (65.9% [ p < 0.05], 57.6% [ p < 0.05], and 16.5% [ p < 0.05], respectively, in the ON group). ON patients were more likely to be treated with glucocorticoid (GC) and to receive a high dose of prednisolone at the initial stage of SLE ( p < 0.05). The percentage of patients who received hydroxychloroquine was much higher in the control group ( p < 0.001). Cox regression analysis suggested that CNS involvement and GC therapy were two independent risk factors for ON in SLE patients. The presence of anti-phospholipid antibodies (aPLs) was a risk factor for multiple joint necrosis (odds ratio: 6.28, p = 0.009). Conclusions ON remains a serious and irreversible complication in SLE. In addition to glucocorticoid therapy, we found that CNS system involvement was a risk factor for ON, while the administration of hydroxychloroquine was a protective factor. The clinical characteristics of multiple site ON patients were distinct from isolated femoral head necrosis patients. The presence of aPLs was a risk factor for multiple site osteonecrosis.

Integrated analysis of transcriptome and proteome to explore the genes related to steroid-induced femoral head necrosis

2021 ◽  
Vol 401 (1) ◽  
pp. 112513
Author(s):  
Ning Yang ◽  
Hongzhi Wang ◽  
Weicheng Zhang ◽  
Houyi Sun ◽  
Meng Li ◽  
...  
Keyword(s):  
Femoral Head ◽  
Femoral Head Necrosis ◽  
Integrated Analysis
Sign in / Sign up

Export Citation Format

Share Document